Try a new search

Format these results:

Searched for:

in-biosketch:true

person:tanejs01

Total Results:

845


Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer

Taneja, Samir S
PMID: 28093144
ISSN: 1527-3792
CID: 2548422

Re: Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

Taneja, Samir S
PMID: 28093145
ISSN: 1527-3792
CID: 2548412

Re: Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life after Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer

Taneja, Samir S
PMID: 27979505
ISSN: 1527-3792
CID: 2548472

Re: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study

Taneja, Samir S
PMID: 27979506
ISSN: 1527-3792
CID: 2548462

Re: Magnetic Resonance Imaging-Ultrasound Fusion Biopsy during Prostate Cancer Active Surveillance

Taneja, Samir S
PMID: 28093146
ISSN: 1527-3792
CID: 2548402

Re: Pathological Analysis of the Prostatic Anterior Fat Pad at Radical Prostatectomy: Insights from a Prospective Series

Taneja, Samir S
PMID: 28208517
ISSN: 1527-3792
CID: 2548392

Re: Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

Taneja, Samir S
PMID: 28208518
ISSN: 1527-3792
CID: 2548382

Re: Quantified Clinical Risk Change as an End Point during Prostate Cancer Active Surveillance

Taneja, Samir S
PMID: 28208519
ISSN: 1527-3792
CID: 2548372

Small Renal Mass [Editorial]

Taneja, Samir S
PMID: 28411924
ISSN: 1558-318x
CID: 2532272

The role of whole-lesion apparent diffusion coefficient analysis for predicting outcomes of prostate cancer patients on active surveillance

Tamada, Tsutomu; Dani, Hasan; Taneja, Samir S; Rosenkrantz, Andrew B
PURPOSE: To explore the role of whole-lesion apparent diffusion coefficient (ADC) analysis for predicting outcomes in prostate cancer patients on active surveillance. METHODS: This study included 72 prostate cancer patients who underwent MRI-ultrasound fusion-targeted biopsy at the initiation of active surveillance, had a visible MRI lesion in the region of tumor on biopsy, and underwent 3T baseline and follow-up MRI examinations separated by at least one year. Thirty of the patients also underwent an additional MRI-ultrasound fusion-targeted biopsy after the follow-up MRI. Whole-lesion ADC metrics and lesion volumes were computed from 3D whole-lesion volumes-of-interest placed on lesions on the baseline and follow-up ADC maps. The percent change in lesion volume on the ADC map between the serial examinations was computed. Statistical analysis included unpaired t tests, ROC analysis, and Fisher's exact test. RESULTS: Baseline mean ADC, ADC0-10th-percentile, ADC10-25th-percentile, and ADC25-50th-percentile were all significantly lower in lesions exhibiting >/=50% growth on the ADC map compared with remaining lesions (all P /=50% growth observed for ADC0-10th-percentile (585 +/- 308 vs. 911 +/- 336; P = 0.001). ADC0-10th-percentile achieved highest performance for predicting >/=50% growth (AUC = 0.754). Mean percent change in tumor volume on the ADC map was 62.3% +/- 26.9% in patients with GS >/= 3 + 4 on follow-up biopsy compared with 3.6% +/- 64.6% in remaining patients (P = 0.050). CONCLUSION: Our preliminary results suggest a role for 3D whole-lesion ADC analysis in prostate cancer active surveillance.
PMID: 28396920
ISSN: 2366-0058
CID: 2528182